Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q3 2017 Earnings Presentation
24 slides from Arcticzymes Technologies Asa's earnings presentation, Oct 19, 2017
Slide 1: Q3 2017 Presentation
Q3 2017 Presentation 19.10.2017, Oslo
Slide 2: Agenda
Agenda • Highlights • Q3 Financials • BetaGlucans • Animal- and Consumer health • Cancer • Advanced wound care • Enzymes • Molecular and new markets • Outlook 2
Slide 3: Highlights for Q3 2017
Highlights for Q3 2017 Tromsø • New CEO commenced on Oct 2 • Q3 sales of NOK 14.4 mill (NOK 21.1 mill) • EBITDA of NOK -7.3 mill (NOK -5.9 mill) • New supply agreement for M-Gard and a renewed supply agreement for M-Glucan • Woulgan sales of NOK 0.4 million • ArcticZymes commercially ready to enter
Slide 4: Q3 Financials
Q3 Financials ites. BIOTEC ret” PHARMACON
Slide 5: Financial highlights Q3 2017
Financial highlights Q3 2017 NOK million Q3 2017 Q3 2016 9M 2017 9M 2016 Sales Enzymes 5.6 6.0 22.9 21.9 Sales BetaGlucans 8.8 15.1 26.1 31.8 Other revenues 1.8 1.4 4.9 5.0 Total revenues 16.3 22.5 53.9 58.7 Enzymes -0.8 -0.4 4.4 5.2 BetaGlucans -4.8 -3.7 -14.1 -12.3 Corporate unallocated -1.7 -1.8
Slide 6: Cash flow and cash position
Cash flow and cash position NOK million Q3 2017 Q3 2016 9M 2017 9M 2016 Operating activities -4.3 -2.9 -20.6 -16.6 Investing activities -0.9 0 -3.9 0 Financing activities 0 0 0 0 Changes in cash and cash equivalent -5.3 -3.0 -24.5 -16.6 Cash and cash equivalents at the 38.4 64.7 57.7 78.3 beginning
Slide 7: Beta-glucans
BIOTEC °° PHARMACON
Slide 8: Beta-glucans – segment numbers
Beta-glucans – segment numbers NOK million Q3 2017 Q3 2016 9M 2017 9M 2016 Sales Animal & Consumer Health 8.4 15.1 24.4 31.6 Sales Woulgan 0.4 0 1.7 0.2 Other revenues 0.8 0.8 2.1 1.8 Total revenues 9.6 15.9 28.2 33.6 Cost of Goods -5.8 -10.1 -15.9 -18.8 Personnel expenses -5.8 -5.5 -15.8 -15.6 Oper
Slide 9: Activities outside Woulgan®
Activities outside Woulgan® Animal health • Renewed supply agreement with largest customer • Signed a supply agreement within the pet- market • Sales experiences annual and seasonal fluctuations driven by demand for health feed within the aquaculture sector Consumer Health: • One new supply agreemen
Slide 10: Cancer adjuvant
Cancer adjuvant • About 150 patients treated with the vaccine/SBG combination at Memorial Sloan Kettering Cancer Center • Study increased from 145 to 185 patients • Biotec and MSKCC continue to discuss on how to move forward 10
Slide 11: Status Woulgan®
Status Woulgan® • Third quarter sales low due to earlier stocking • Underlying consumption of Woulgan continues to build, especially in Germany • Continued excellent reaction from clinicians • recognising the issue of stalled wounds • engaging with a genuinely new and different therapy approach • wi
Slide 12: Highlights Germany
Highlights Germany • Consumption of Woulgan continues to build • Training wound nurses to support adoption • Excellent reaction to Woulgan symposium at WundDACH congress. • Clinicians recognise issue of stalled wounds and engage with novel SBG treatment • Gained ethics approval for 2 leading centres
Slide 13: Highlights UK
Highlights UK •Panel upheld Biotec’s Drug Tariff (DT) appeal • Biotec corresponding with DT in re-assessment of application •Making good progress building additional UK evidence 13
Slide 14: Highlights Nordics
Highlights Nordics Norway • Launched Woulgan to local wholesaler sales team • Organizing local workshops to grow sales Nordic region • Recruited additional patients for case series ; on track to submit for publication 1st quarter 2018 • builds clinician support • creates Nordic evidence 14
Slide 15: Research and Development
Research and Development • Pilot plant for production of Woulgan® dry layer is being tested • Aim to develop proprietary methods for production that can be patent protected • Such gel-forming dry layer is well suited to more exuding- and larger surface wounds
Slide 16: ArcticZymes – Molecular and new markets
ArcticZymes Molecular and new markets
Slide 17: Enzymes – Segment Numbers
Enzymes – Segment Numbers NOK million Q3 2017 Q3 2016 9M 2017 9M 2016 Sales enzymes 5.6 6.0 22.9 21.9 Other revenues 1.1 0.6 2.7 3.2 Total revenues 6.7 6.6 25.6 25.1 Cost of goods -0.1 -0.1 0.2 -0,3 Personnel expenses -5.5 -5.0 -14.7 -14.1 Operating expenses -1.8 -1.8 -6.7 -5.4 EBITDA -0.8 -0.4 4.4
Slide 18: Commercial Updates
Commercial Updates • IsoPolTM moving forward with leading Next Generation Sequencing Companies (NGS) companies Early development phase Receiving follow-on orders Strategically important to enter the next phase of the NGS market early on as the leading technologies for the future are being desi
Slide 19: Expanding into New Markets
Expanding into New Markets Molecular Bio-Manufacturing • ArcticZymes core market • New market for ArcticZymes • Customers: Molecular diagnostics and molecular • Customers: Bio-manufacturers of gene therapy kit manufacturers viruses, vaccines, proteins and other bio-products • Enzymes: end up as comp
Slide 20: Bio-Manufacturing: Gene Therapy Viruses
Bio-Manufacturing: Gene Therapy Viruses SAN HQ ELISA immunoassay launched • Milestone: enables ArcticZymes to offer a complete solution • Essential for commercial success Key focus is gene therapy viruses • Early phase: over 30 clinical trials ongoing • Over 1.5$Bil annual innovation investment (del
Slide 21: Expanding the Product Range
Expanding the Product Range Product Lines Phosphatase DNase UNG Nuclease Polymerase Proteinase Next? Pre 2016 dsDNase rSAP HL-dsDNase SAN Cod UNG A’SAP®kits PCR decont. kit HL-SAN Heat&Run®kit Doubled 2016 GF DNase product HL-ExoI GF Cod UNG IsoPol™ GF HL-DNase offering SAN HQ IsoPol™ II (Q4) Dr
Slide 22: Outlook 2017
Outlook 2017 ‘ah - o@ete. BIOTEC ret” PHARMACON
Slide 23: Outlook 2017
Outlook 2017 • Commercial traction and sales in core markets for Woulgan® • Retain position in the Animal Health market • Building commercial platform in Consumer Health • Launch further products in ArcticZymes including Polymerases • Continue to widen ArcticZymes’ commercial platform with new agree
Slide 24: Contact
Contact: Barge Sgrvoll bso@biotec.no TIf: 95290187 www.biotec.no atest, BIOTEC ret” PHARMACON
ArcticZymes Technologies — Q3 2017 Earnings Presentation on 6ix